Tratamiento endodóntico obturado con pasta lentamente reabsorbible: seguimiento de un caso a 6 años / Endodontic treatment filled with slowly resorbable paste: a 6-year follow-up case

Reporte de un caso clínico de un tratamiento endodóntico de incisivo central superior con diagnostico de necrosis pulpar y proceso apical preexistente, obturado con pastalentamente reabsorbible. El seguimiento post tratamiento fue realizado mediante controles radiográficos inmediatos y a distancia, en los cuales se evaluó la calidad de la obturación y la reparación de los tejidos dañados.

Reconstrucción de una pieza tratada endodónticamente en una sesión con utilización de poste preformado: reporte de caso / Reconstruction of an endodontically treated tooth in a single session with a preformed post

La realización de un anclaje intra-radicular provisorio para iniciar la confección del definitivo en la sesión siguiente aumenta el riesgo de fractura radicular y el riesgo de filtración coronaria de la obturación endodóntica. En el presente trabajo se reporta el caso clínico de un paciente con diagnóstico de pulpitis infiltrativa de la pieza 2.1, al que se le realizó tratamiento endodóntico y posterior anclaje intra-radicular definitivo. El anclaje intra-radicular fue realizado mediante la instalación de un poste orgánico y a continuación se reconstruyó el muñón coronario con resinas compuestas, colocando una corona de acrílico como elemento provisorio, en una misma sesión.

Anandamide injected into the lateral ventricle of the brain inhibits submandibular salivary secretion by attenuating parasympathetic neurotransmission

Our objective was to determine the effect of arachidonylethanolamide (anandamide, AEA) injected intracerebroventricularly (icv) into the lateral ventricle of the rat brain on submandibular gland (SMG) salivary secretion. Parasympathetic decentralization (PSD) produced by cutting the chorda tympani nerve strongly inhibited methacholine (MC)-induced salivary secretion while sympathetic denervation (SD) produced by removing the superior cervical ganglia reduced it slightly. Also, AEA (50 ng/5 µL, icv) significantly decreased MC-induced salivary secretion in intact rats (MC 1 µg/kg: control (C), 5.3 ± 0.6 vs AEA, 2.7 ± 0.6 mg; MC 3 µg/kg: C, 17.6 ± 1.0 vs AEA, 8.7 ± 0.9 mg; MC 10 µg/kg: C, 37.4 ± 1.2 vs AEA, 22.9 ± 2.6 mg). However, AEA did not alter the significantly reduced salivary secretion in rats with PSD, but decreased the slightly reduced salivary secretion in rats with SD (MC 1 µg/kg: C, 3.8 ± 0.8 vs AEA, 1.4 ± 0.6 mg; MC 3 µg/kg: C, 14.7 ± 2.4 vs AEA, 6.9 ± 1.2 mg; P < 0.05; MC 10 µg/kg: C, 39.5 ± 1.0 vs AEA, 22.3 ± 0.5 mg; P < 0.001). We showed that the inhibitory effect of AEA is mediated by cannabinoid type 1 CB1 receptors and involves GABAergic neurotransmission, since it was blocked by previous injection of the CB1 receptor antagonist AM251 (500 ng/5 µL, icv) or of the GABA A receptor antagonist, bicuculline (25 ng/5 µL, icv). Our results suggest that parasympathetic neurotransmission from the central nervous system to the SMG can be inhibited by endocannabinoid and GABAergic systems.

Immunoreactive erythropoietin in rodent submaxillary gland. Autonomic control of exocrine secretion and factors influencing its concentration

The SMG of mice and rats contain a heterologous group of biologically active factors. Some are well known, can be obtained at high purity and are well-characterized. There is strong evidence for the presence of others although they have not been purified. Finally, some of them are questionable and/or have not yet been characterized. EPO would be one of the factors whose presence in the SMG is strongly suspected, although its biological activity has not been demonstrated yet. Its presence in the gland, therefore, is only supported by radioimmunoassay data and immunocytochemical methods. Immunoreactive EPO is undetectable in the mouse SMG until the 30th day of postnatal life, increasing thereafter at a uniform rate and reaching adult levels by 50-60 days of age. The parallelism between its concentration in extracts of the gland, the size and relative proportion of GCT cells, could be accepted as indirect evidence for its localization in these cells. The rise in iEPO concentration in SMGs after androgen treatment, its fall following orchiectomy, and its reduction after duct ligation in proportion to the degree of degranulation of GCT cells lend support to the above hypothesis. Salivary secretions induced by either NE or ISO contain high levels of iEPO. A significant depletion of gland content is also observed. These two sets of data indicate that SMG exocrine iEPO secretion occurs and that this secretion is mediated by adrenergic receptors. The question whether the SMG also functions as an endocrine organ in relation to EPO can not be answered at present.

Physiological role of alpha-adrenoceptors in salivary secretion

The submaxillary gland (SM) of rat is innervated by both branches of the autonomic nervous system. Secretion is mediated by the activation of both muscarinic-cholinergic and alpha/beta adrenergic receptors. Studies of the relative affinity of pharmacological agonists and antagonists have warranted a subclassification of alpha adrenoceptors into types alpha 1 and alpha 2. Our studies involve an analysis of the physiologic role of both types of alpha adrenoceptors in salivary secretion. Dose response curves (DRC) to noradrenaline (NA) following administration of alpha adrenoceptor antagonists, i.e. prazosin (alpha 1 antagonist), yohimbine (alpha 2 antagonist) and phentolamine (alpha 1-alpha 2 antagonist) were constructed. Our results demonstrate that prazosin is 100 times more effective than yohimbine in blocking NA-induced salivary secretion. The alpha 2 agonist clonidine (10 micrograms/Kg) blocked the DRCs to methacholine, noradrenaline and substance P-but failed to modify the DRC to isoproterenol. Our results reveal that the subtypes of alpha adrenergic receptors play antagonistic roles in salivary secretion. Alpha 1 stimulation elicits profuse salivary secretion whereas alpha 2 stimulation inhibits salivary secretion induced by 3 different types of agonists, i.e. alpha 1, muscarinic-cholinergic and neurokininergic without affecting beta receptor mediated responses.